Rockefeller Capital Management L.P. Arvinas, Inc. Transaction History

Rockefeller Capital Management L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 06, 2023	BUY	$32.47 - $57.24 $5,909 - $10,417	182 Added 9.01%	2,202 $75,000
Q2 2022 Aug 12, 2022	BUY	$36.01 - $74.24 $72 - $148	2 Added 0.1%	2,020 $85,000
Q1 2022 May 13, 2022	BUY	$60.27 - $81.57 $482 - $652	8 Added 0.4%	2,018 $135,000
Q4 2021 Feb 14, 2022	BUY	$65.85 - $96.21 $658 - $962	10 Added 0.5%	2,010 $165,000
Q3 2021 Nov 12, 2021	SELL	$73.2 - $107.87 $805 - $1,186	-11 Reduced 0.55%	2,000 $164,000
Q2 2021 Aug 10, 2021	BUY	$60.45 - $84.26 $61,114 - $85,186	1,011 Added 101.1%	2,011 $154,000
Q1 2021 May 11, 2021	BUY	$58.19 - $91.37 $58,190 - $91,370	1,000 New	1,000 $66,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $997M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.